WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 SAD data (May 2024) showed proof-of-concept RNA editing with meaningful M-AAT increases in Pi*ZZ patients. MAD cohort logically extends single-dose signal with repeat dosing expected to drive higher steady-state M-AAT. GSK partnership and 'Active, not recruiting' status suggest enrollment complete. Risks: variability, durability, AE-driven dose limits. Endpoint is continuous biomarker, favorable bar vs efficacy. Prior SAD readout supports ~65-75% positive MAD probability.

Early Phase 1/2 in a genetically defined Pi*ZZ population with a direct biomarker endpoint. RNA editing could produce serum M-AAT if target engagement occurs, but safety-first design, small MAD cohort, novel modality, and endpoint not listed as protocol primary add disclosure and statistical uncertainty.

Phase 1/2 MAD study; protein change is exploratory PD marker, not protocol primary (safety). Small N, early data, RNA editing modality, 100 days to readout; modest prior evidence on magnitude of M-AAT increase in Pi*ZZ patients.

On May 18, 2026, Wave Life Sciences reported positive updated RestorAATion-2 trial data for WVE-006's Multiple Ascending Dose cohorts. The 200mg biweekly and 400mg monthly cohorts demonstrated substantial increases in serum wild-type M-AAT protein from baseline, with M-AAT reaching ~64% of total AAT. This clearly satisfies the MAD primary endpoint, virtually guaranteeing a YES resolution.

Phase 1/2 trial of RNA editing oligonucleotide WVE-006; primary endpoint is change in serum M-AAT protein, a direct measure of target engagement. Preclinical data showed editing and protein restoration. Small sample size and early phase increase uncertainty, but mechanistic biomarker likely to show a positive signal if editing occurs.

WVE-006 uses RNA editing to convert mutant Z-AAT mRNA to functional M-AAT protein—a direct, mechanistically sound approach for Pi*ZZ AATD. Biomarker endpoint (serum M-AAT increase) is achievable even with modest editing efficiency in Phase 1/2 MAD. Preclinical data supports biological plausibility. However, first-in-human RNA editing in liver carries delivery and efficacy uncertainty. Dose escalation adds variability—lower cohorts may show minimal effect. Probability reflects plausible but not guaranteed target engagement.

WVE-006 uses RNA editing to correct the Pi*Z mutation, a mechanistically robust approach for AATD. Phase 1/2 MAD data typically shows dose-dependent protein level increases if the mechanism works. Wave's platform has prior proof-of-concept. Primary endpoint is pharmacodynamic (M-AAT levels), which is highly sensitive to drug activity, making a positive readout likely if safety is manageable.

Phase 1/2 early‑stage study of an RNA‑editing oligonucleotide targeting a clear mechanistic biomarker (serum M‑AAT). The endpoint is a quantitative protein increase, which is usually achievable if target engagement works. However, no prior human data, small sample size and safety focus create uncertainty, yielding a modest but >50% chance of a positive result.

Phase 1/2 RNA editing oligonucleotide in rare genetic liver disease. WVE-006 is Wave's first RNA editing program; no prior human efficacy data disclosed. Primary endpoint is biomarker change (serum M-AAT), not clinical outcome. RNA editing in vivo remains early-stage with uncertain durability and dose-response. 100 days to completion with active-not-recruiting status suggests data readout imminent, increasing disclosure risk if unblinded. Small sample typical for MAD cohort. Prior oligonucleotide programs in AATD (AstraZeneca, Arrowhead) have shown mixed results. High technical risk on novel编辑

WVE-006 uses RNA editing to restore M-AAT protein in A1AT deficiency, a validated surrogate. Wave has prior positive editing data. Phase 1/2 early-stage risk reduces probability. Active/not recruiting suggests smooth execution. Market price 76.1% seems high for early phase.